Wells Fargo & Company Autolus Therapeutics PLC Transaction History

Wells Fargo & Company

  • $433 Billion
  • Q4 2024

A detailed history of Wells Fargo & Company transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Wells Fargo & Company holds 266,315 shares of AUTL stock, worth $516,651. This represents 0.0% of its overall portfolio holdings.

Number of Shares
266,315
Previous 385,873 30.98%
Holding current value
$516,651
Previous $1.4 Million 55.36%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
SELL
$2.18 - $4.8 $260,636 - $573,878
-119,558 Reduced 30.98%
266,315 $625,000
Q3 2024

Nov 13, 2024
BUY
$3.38 - $4.69 $18,816 - $26,109
5,567 Added 1.46%
385,873 $1.4 Million
Q2 2024

Aug 13, 2024
BUY
$3.33 - $5.68 $11,768 - $20,073
3,534 Added 0.94%
380,306 $1.32 Million
Q1 2024

May 10, 2024
SELL
$5.39 - $7.29 $165,354 - $223,642
-30,678 Reduced 7.53%
376,772 $2.4 Million
Q4 2023

Feb 09, 2024
SELL
$2.13 - $6.63 $319,659 - $994,997
-150,075 Reduced 26.92%
407,450 $2.62 Million
Q3 2023

Nov 13, 2023
BUY
$2.32 - $3.36 $88,352 - $127,958
38,083 Added 7.33%
557,525 $1.3 Million
Q2 2023

Aug 15, 2023
BUY
$1.64 - $3.21 $52,599 - $102,954
32,073 Added 6.58%
519,442 $1.24 Million
Q1 2023

May 12, 2023
BUY
$1.75 - $2.25 $195,489 - $251,343
111,708 Added 29.74%
487,369 $896,000
Q4 2022

Feb 13, 2023
SELL
$1.74 - $3.27 $24,669 - $46,362
-14,178 Reduced 3.64%
375,661 $713,000
Q3 2022

Nov 14, 2022
BUY
$2.04 - $3.76 $52,803 - $97,323
25,884 Added 7.11%
389,839 $834,000
Q2 2022

Aug 12, 2022
BUY
$2.04 - $4.68 $253,612 - $581,817
124,320 Added 51.88%
363,955 $1.03 Million
Q1 2022

May 16, 2022
BUY
$3.52 - $5.46 $142,426 - $220,922
40,462 Added 20.32%
239,635 $1 Million
Q4 2021

Feb 14, 2022
SELL
$5.1 - $7.0 $276,710 - $379,799
-54,257 Reduced 21.41%
199,173 $1.03 Million
Q3 2021

Nov 15, 2021
BUY
$5.32 - $7.37 $587,466 - $813,839
110,426 Added 77.22%
253,430 $1.66 Million
Q2 2021

Aug 16, 2021
BUY
$4.78 - $7.96 $348,309 - $580,029
72,868 Added 103.9%
143,004 $950,000
Q1 2021

May 13, 2021
BUY
$5.49 - $9.36 $238,051 - $405,858
43,361 Added 161.95%
70,136 $401,000
Q4 2020

Feb 09, 2021
BUY
$8.13 - $12.79 $83,673 - $131,634
10,292 Added 62.44%
26,775 $239,000
Q3 2020

Nov 05, 2020
BUY
$11.64 - $16.3 $46,641 - $65,314
4,007 Added 32.12%
16,483 $191,000
Q2 2020

Aug 13, 2020
SELL
$5.38 - $16.14 $13,154 - $39,462
-2,445 Reduced 16.39%
12,476 $200,000
Q1 2020

May 14, 2020
BUY
$4.2 - $13.0 $62,668 - $193,973
14,921 New
14,921 $89,000

Others Institutions Holding AUTL

# of Institutions
112
Shares Held
156M
Call Options Held
0
Put Options Held
116K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $176M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email